Figure 6. Administration of IONIS-APOL1_Rx reduces kidney and plasma APOL1 protein levels.

Female APOL1 G0– and G1–transgenic mice (n = 3–4) were treated with 50 mg/kg IONIS-APOL1_Rx or control ASO 1 time per week for 4 weeks and challenged with a single dose of IFN-γ (1.125 × 10⁷ U/kg) or vehicle (PBS). Study endpoints were evaluated 48 hours after IFN-γ challenge. (A) IHC analysis of APOL1 protein in kidney tissues from IONIS-APOL1_Rx– or PBS-treated APOL1 G1–transgenic mice 48 hours after IFN-γ or PBS challenge. Representative images are shown (scale bar: 50 μm). (B) Plasma APOL1 levels were measured by ELISA. Data are presented as mean ± SD. Two-way ANOVA with Tukey’s multiple comparisons test, ***P < 0.001. Similar statistical significance was achieved when comparing APOL1 ASO–treated groups challenged with PBS or IFN-γ in comparison to respective PBS- or control ASO–treated groups.